Basic Desogen Information

• INN (International Nonproprietary Name): Desogestrel (combined with Ethinylestradiol in many contraceptives).
• Brand Names Available In Australia: Marvelon, Mercilon (tab 0.150 mg/0.030 mg in 21 or 28‑tab blister) distributed by Merck and Organon.
• ATC Code: G03AA09 — Progestogens and estrogens, fixed combinations (Desogestrel and Ethinylestradiol).
• Forms & Dosages: Combined oral tablets 0.150 mg desogestrel + 0.030 mg ethinylestradiol; combined variant 0.150 mg desogestrel + 0.020 mg ethinylestradiol; progestogen‑only tablet 75 μg desogestrel.
• Manufacturers In Australia: Merck, Organon (originator/suppliers), with generics and other distributors possible via wholesalers.
• Registration Status In Australia: Approved and registered; prescription‑only (Rx) in most markets per product information.
• OTC / Rx Classification: Prescription‑only (Rx) according to available regulatory information.

Latest Research Highlights

What does recent research tell Australians worried about safety and pregnancy prevention?

Recent cohort studies and meta‑analyses from 2022 to 2025 show that desogestrel/ethinylestradiol combined oral contraceptives maintain high contraceptive efficacy when taken correctly.

Typical‑use pregnancy rates across COC literature remain around 6–9% per year, while perfect‑use rates are consistently below 1% per year.

Multiple analyses published in the period reinforce that efficacy for EE/desogestrel 150/30 is comparable to other combined oral contraceptives when adherence is good.

Safety studies continue to show a modestly higher venous thromboembolism relative risk for third‑generation progestins, including desogestrel, compared with levonorgestrel‑based pills.

The absolute risk of VTE for healthy non‑smokers under 35 remains low, despite that relative increase in some analyses.

Australian TGA pharmacovigilance data from 2022–24 mirror global signals, with common reports of breakthrough bleeding, mood changes and nausea.

The TGA also recorded rare serious reports such as thromboembolism and hepatic events, consistent with international post‑marketing findings.

Small Australian clinic audits from 2023–25 support the use of desogestrel 75 μg progestogen‑only tablets for oestrogen‑intolerant patients, noting acceptable contraceptive performance but higher rates of irregular bleeding.

Summary table of outcomes (concise):

• Efficacy: Comparable to other combined pills when taken correctly; perfect‑use <1%/yr, typical‑use ~6–9%/yr.
• VTE Relative Risk: Modestly higher for third‑generation progestins (desogestrel) vs levonorgestrel; absolute risk low in young healthy non‑smokers.
• Bleeding Profile: Common breakthrough or irregular bleeding; progestogen‑only formulations show more irregular bleeding.
• Mood And Nausea: Frequently reported in TGA and clinic audits; generally mild to moderate.

Clinical Effectiveness In Australia

How effective is Marvelon/Mercilon for people living in Australia?

The desogestrel/ethinylestradiol combination, commonly marketed in Australia as Marvelon or Mercilon, is recognised as an effective combined oral contraceptive when used correctly.

Product formulations available include 0.150 mg desogestrel with 0.030 mg ethinylestradiol, and a 0.150 mg desogestrel with 0.020 mg ethinylestradiol variant.

TGA adverse‑event reporting aligns with international data, highlighting breakthrough bleeding, mood disturbance and rare thromboembolism as the most reported issues.

PBS utilisation varies by brand and subsidy status, so many patients receive these pills privately through community pharmacies or telehealth prescriptions.

Real‑world adherence data from Australian primary care show that missed pills are the main driver of contraceptive failure rather than any intrinsic pharmacologic inferiority of desogestrel combinations.

Clinical audits in Australia also note that desogestrel 75 μg progestogen‑only tablets (minipill‑type) are a useful alternative for women contraindicated to oestrogen.

Data highlight: TGA report counts and dispensing trends are used by clinicians and pharmacists to counsel on common side effects and to manage expectations about bleeding and mood changes.

Indications And Expanded Uses

Why might a clinician choose desogestrel/ethinylestradiol beyond contraception?

The TGA‑approved indication for combined desogestrel/ethinylestradiol formulations is contraception in adult women.

Available combined tablet strengths include 0.150 mg desogestrel + 0.030 mg EE and a 0.150 mg desogestrel + 0.020 mg EE variant for some brands.

The desogestrel 75 μg tablet is a progestogen‑only option commonly prescribed for women who cannot take oestrogen.

Common off‑label uses in Australian practice include cycle regulation, treatment of dysmenorrhoea, management of acne and adjunctive support for endometriosis symptoms, where clinicians judge the benefits outweigh risks.

These off‑label uses are supported by observational studies and clinical experience, but formal evidence quality varies from RCTs to cohort studies depending on the indication.

Contraindications include pregnancy, severe hepatic disease and known hormone‑sensitive cancers, and it is not indicated post‑menopause.

For adolescents, treatment should only begin after menarche with clear counselling about adherence and side effects.

Definitions and evidence levels:

• TGA‑Approved Use: Contraception — evidence: regulatory submission data and product trials.
• Common Off‑Label Uses: Cycle regulation, dysmenorrhoea, acne, endometriosis — evidence: RCTs and observational studies depending on topic.

Composition And Brand Landscape

Which brands and strengths will patients recognise at the pharmacy counter?

The active ingredients are desogestrel (INN) combined with ethinylestradiol in fixed oral tablet formulations.

Common combined strengths include 0.150 mg desogestrel + 0.030 mg ethinylestradiol and 0.150 mg desogestrel + 0.020 mg ethinylestradiol.

Progestogen‑only tablets of desogestrel 75 μg are available for patients intolerant to oestrogen.

In Australia, the brands patients most commonly see are Marvelon and Mercilon, supplied by Merck and Organon.

Generics and imported equivalents may be supplied by other manufacturers such as Teva, Sandoz or local distributors depending on supply.

Packaging is typically 21 or 28‑tab blisters, with the 21/7 schedule commonly used for combined pills.

Note on naming: searches for Desogen commonly point to US brand information; Australian users will more often encounter Marvelon or Mercilon.

Brand table (quick view):

Contraindications And Special Precautions

Who should not take desogestrel/ethinylestradiol and what checks should a pharmacist perform?

Absolute contraindications include pregnancy, current or past thromboembolic disorders, severe liver disease or hepatic tumours, and known oestrogen/progestin‑sensitive cancers such as breast or endometrial cancer.

Other absolute exclusions are unexplained vaginal bleeding, major surgery with prolonged immobilisation, cholestatic jaundice, uncontrolled hypertension, significant cerebrovascular or cardiovascular disease, and allergy to components.

Relative cautions include controlled hypertension, diabetes particularly with vascular complications, migraine without aura, obesity and hyperlipidaemia.

Smoking increases cardiovascular risk, especially for people over 35 years, and should factor into prescribing decisions.

Special Australian considerations include higher smoking and cardiovascular risk in some Indigenous communities and reduced access to emergency services in remote areas, which calls for culturally safe counselling and conservative risk assessment.

Daily‑life advice: no routine driving or work restrictions are required, but patients should be careful if they experience dizziness or severe headache while taking the pill.

Pharmacy screening checklist:

• Ask about personal or family VTE history, migraine history, smoking status, current medicines and pregnancy status.
• Check liver disease, recent surgery or immobilisation, and any unexplained bleeding.
• Use culturally appropriate communication for Indigenous and CALD patients and offer printed information.

Dosage Guidelines

How should patients take Marvelon, and what should they do if they miss a pill?

Standard adult dosing for the combined desogestrel/ethinylestradiol pill is one active tablet daily for 21 consecutive days, followed by an inactive tablet for 7 days, or a 28‑day regimen as per the product leaflet.

Take the tablet at the same time each day to maintain efficacy.

Desogestrel 75 μg progestogen‑only tablets are taken continuously at the same time every day and have a more critical dosing window, typically within 12 hours to maintain protection.

Missed‑pill rules from product information:

• If one combined tablet is missed and less than 12 hours have passed, take it as soon as remembered and continue the pack.
• If more than 12 hours have passed, efficacy may be reduced; follow the leaflet for backup contraception and consider emergency contraception if unprotected sex occurred.
• If vomiting or severe diarrhoea occurs within 3–4 hours of taking the tablet, take another tablet as soon as possible.

Adolescents follow the same dosing after menarche, but evidence in those under 16 is limited, so counsel carefully about adherence.

Interactions Overview

Which medicines and supplements can make the pill less effective?

Enzyme‑inducing drugs such as rifampicin, rifabutin and certain anticonvulsants like carbamazepine and phenobarbital can lower hormone levels and reduce contraceptive effectiveness.

High‑dose topiramate and some HIV protease inhibitors can also interact and may necessitate alternative or additional contraception methods.

St John’s wort is an herbal inducer that reduces hormonal contraceptive levels and should be avoided in people relying on the pill.

Most antibiotics that are not enzyme inducers have minimal interaction potential, but gastrointestinal upset from antibiotics may impair absorption temporarily.

Alcohol and coffee do not have direct pharmacokinetic interactions with desogestrel/ethinylestradiol, but alcohol may impact adherence.

Pharmacist action checklist:

• Review the patient's medicines for enzyme inducers and advise backup contraception while on the interacting medication and for the recommended period afterwards.
• Warn against St John’s wort while using hormonal contraception.
• Document interactions in the patient record or eHealth summary and liaise with the prescriber if needed.

Cultural Perceptions And Patient Habits In Australia

How do Australians actually get and feel about the pill?

Urban younger patients often favour telehealth and online pharmacies for convenience and privacy.

Rural and remote women may rely more on community pharmacists at chains like TerryWhite, Chemist Warehouse or Priceline, and often prefer long‑acting methods when access to prescribers is limited.

Price sensitivity affects brand choice, making PBS subsidy status and pharmacy discounts important factors in decision making.

Patient forums commonly show confusion about brand names, with searches for Desogen often leading to Marvelon or Mercilon information instead.

Concerns expressed online include mood changes, irregular bleeding and clotting risk, and these are legitimate topics for pharmacist counselling.

For Indigenous and culturally diverse communities, privacy, culturally safe counselling and translated or pictorial materials improve uptake and adherence.

Patient personas for pharmacists:

• Urban Student: Wants telehealth, cost‑sensitive, quick repeat prescriptions.
• Rural Parent: Prefers multi‑month supplies, may consider IUD for fewer visits.
• Indigenous Community Member: Values culturally safe support and clear printed instructions.

Availability And Pricing Patterns

Where can patients buy Marvelon or Mercilon, and how much does it cost?

Marvelon and Mercilon are distributed in Australia by Merck and Organon and are commonly stocked in major pharmacy chains and independent chemists.

Availability includes community pharmacies and online dispensaries, with telehealth e‑prescriptions a frequent route for repeat supplies.

PBS listing and subsidy vary by product and pack size, so some packs are private‑prescription items requiring full payment.

Pricing patterns are shaped by competition among chains, generics availability and whether a formulation is PBS‑listed.

Rural patients should consider potential mail delays for online orders and plan supplies accordingly.

Purchase note: In our online pharmacy, desogen is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Advice: Always check with the dispensing pharmacist about current PBS status and available discounts for your particular pack.

Comparable Medicines And Preferences

Which alternatives might suit patients better, and how to choose?

Alternatives to desogestrel/ethinylestradiol in Australia include combined pills with other progestins such as drospirenone+EE (Yasmin), levonorgestrel+EE (Alesse, Levlen) and gestodene+EE (Microgynon, Minulet).

Progestogen‑only options include desogestrel 75 μg tablets, injected depot contraceptives and levonorgestrel or copper IUDs for those preferring non‑daily methods.

Key trade‑offs include VTE risk — levonorgestrel‑based pills have lower VTE relative risk — and differences in cycle control, acne benefits and side‑effect profiles.

Decision checklist for clinicians and pharmacists:

• Consider patient age, smoking status and BMI when assessing VTE risk.
• Assess migraine history and breastfeeding status before choosing combined pills.
• Evaluate likely adherence to daily dosing and consider long‑acting reversible contraception if adherence is a concern.

Top pros/cons at a glance:

FAQ — Top Questions Australian Patients Ask

What answers do people want when they visit the pharmacy counter?

Q1: Can I switch from another pill to Marvelon or Mercilon?

A1: Yes, switching is possible; follow product leaflet guidance for when to start and whether 7 days of backup contraception are needed.

Q2: Is it safe to use while breastfeeding?

A2: Combined pills with ethinylestradiol are generally not recommended in early breastfeeding, and progestogen‑only desogestrel 75 μg is usually preferred.

Q3: What if I miss a desogestrel tablet?

A3: If less than 12 hours late, take the tablet as soon as you remember; if more than 12 hours, use backup contraception and follow the leaflet instructions.

Q4: How concerned should I be about clotting?

A4: The absolute risk of VTE is low in young healthy non‑smokers, but risk increases with age, smoking, obesity and personal or family history of VTE; discuss with your GP if concerned.

Pharmacy leaflets should include links to TGA and PBS information for patients wanting official sources.

Guidelines For Proper Use And Pharmacist Counselling

How should pharmacists structure counselling to be safe and helpful?

Counselling should be structured and patient‑centred, beginning with confirmation of indication and a full medical history focusing on VTE, migraines and liver disease.

Review current medicines and supplements for interactions such as enzyme inducers and St John’s wort.

Explain dosing clearly: 21/7 combined regimens or continuous dosing for combined pills and strict daily timing for desogestrel 75 μg progestogen‑only tablets.

Discuss missed‑pill actions, emergency contraception options and what to do after vomiting or severe diarrhoea.

Cover side effects honestly: common mild effects include nausea, breast tenderness and breakthrough bleeding, while rare serious effects include thromboembolism and hepatic dysfunction.

Offer practical access advice: supply options (monthly repeats, multi‑month supplies), PBS queries and telehealth follow‑up arrangements for rural patients.

Always use culturally appropriate language for Indigenous and CALD patients and offer printed or pictorial instructions when helpful.

Counselling checklist for pharmacists:

• Confirm contraception need and pregnancy status.
• Screen for contraindications and cautions using a simple checklist.
• Review medicines for interactions and advise backup contraception if needed.
• Provide clear written dosing and missed‑pill instructions and an emergency contact plan.

Delivery Across Australia

Final Notes For Patients

Choosing a pill is about matching safety, lifestyle and personal preference.

Desogestrel/ethinylestradiol pills such as Marvelon and Mercilon are effective contraceptives with a known safety profile that requires appropriate screening for thromboembolic and hepatic risks.

If mood changes, persistent bleeding or symptoms suggestive of clotting occur, seek urgent medical assessment.

Pharmacists can help with brand availability, PBS questions, interaction checks and clear instructions on missed pills and emergency contraception.

For complex risk assessments, refer the patient back to their GP for individualised advice and documented decision making.